V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10477850 | 10042513 | 1.75 | 72 | Curative (C) | 2018-09-17 | 2018-09-21 | DABRAFENIB | 01 | N | LANREOTIDE | 100777684 |
| 10477892 | 10042514 | 1.77 | 57 | null | 2019-11-18 | 2019-12-10 | FEC | 02 | null | MELPHALAN | 101565779 |
| 10477963 | 10042515 | 1.77 | 75.2 | Adjuvant (A) | 2019-05-12 | 2019-05-27 | Methotrexate High Dose (3g/m2) | N | N | LENALIDOMIDE + RITUXIMAB | 100766936 |
| 10477994 | 10042516 | 1.71 | 117 | Palliative (P) | 2020-12-12 | 2020-12-23 | Cyclophosphamide Fludarabine (Oral) | 02 | null | CHLORAMBUCIL + OFATUMUMAB | 101443972 |
| 10478176 | 10042519 | 1.76 | 69.05 | Adjuvant (A) | null | 2021-10-16 | CARBOPLATIN + GEMCITABINE | null | N | CHOP | 100836889 |
| 10478198 | 10042520 | null | null | Palliative (P) | 2021-09-09 | 2021-09-12 | Letrozole + Palbociclib | 02 | N | BRENTUXIMAB VEDOTIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 100491735 |
| 10478222 | 10042521 | 1.77 | 80 | Disease modification (D) | 2016-04-04 | 2016-04-30 | CARBOPLATIN + GEMCITABINE | N | N | FLAIR TRIAL | 100132187 |
| 10478223 | 10042522 | 1.7 | 69 | Curative (C) | 2019-10-27 | 2019-10-27 | RIALTO TRIAL | 02 | null | GEMCITABINE + NAB-PACLITAXEL | 100055196 |
| 10478272 | 10042523 | 1.63 | 71.9 | null | 2019-08-10 | 2019-08-26 | AZACITIDINE + VENETOCLAX | 99 | null | THALIDOMIDE | 101321916 |
| 10478348 | 10042524 | 1.74 | 66 | Palliative (P) | 2019-11-09 | 2019-11-14 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100251188 |
| 10478373 | 10042525 | 1.72 | 78.1 | Curative (C) | 2019-03-27 | 2019-03-27 | IDELALISIB + RITUXIMAB | N | null | AML18 TRIAL | 101142860 |
| 10478682 | 10042527 | 1.7 | 84.05 | Curative (C) | 2019-07-16 | 2019-12-25 | FLAIR trial | N | null | BORTEZOMIB + DARATUMUMAB + THALIDOMIDE | 101181935 |
| 10478686 | 10042528 | null | 96.3 | Neo-adjuvant (N) | 2019-02-17 | 2019-02-22 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 02 | N | CAPECITABINE + IRINOTECAN + PANITUMUMAB | 100090242 |
| 10478706 | 10042529 | null | null | null | 2018-09-18 | 2018-10-04 | Vinorelbine (oral) | 02 | null | SAPROCAN TRIAL | 100376229 |
| 10478761 | 10042531 | 1.6 | null | Palliative (P) | 2009-02-03 | 2018-08-18 | AZACITIDINE + VENETOCLAX | 02 | N | ABEMACICLIB + FULVESTRANT | 101475321 |
| 10478853 | 10042532 | 0 | null | Curative (C) | 2019-10-28 | 2019-12-03 | Ifosfamide | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101425103 |
| 10478938 | 10042534 | 1.77 | 105 | Palliative (P) | 2019-04-10 | 2019-04-11 | Apalutamide | 02 | N | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100160650 |
| 10478975 | 10042535 | null | null | 03 | null | 2022-03-28 | Doxorubicin + Ifosfamide | null | null | OBINUTUZUMAB + VENETOCLAX | 100349456 |
| 10478986 | 10042536 | 1.78 | 79.7 | Palliative (P) | 2019-08-15 | 2019-08-27 | THALIDOMIDE | 02 | N | IXAZOMIB + LENALIDOMIDE | 101800283 |
| 10479050 | 10042537 | 1.8 | 65 | null | 2020-02-14 | 2020-02-14 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | SPIRE TRIAL | 101216618 |
| 10479156 | 10042538 | 1.73 | 91 | null | 2022-02-15 | 2022-02-15 | null | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100892089 |
| 10479339 | 10042541 | 1.71 | 72.7 | Curative (C) | 2018-03-28 | 2018-04-12 | Cisplatin + Pemetrexed | 02 | null | IRINOTECAN | 100786757 |
| 10479451 | 10042543 | 1.42 | 55.5 | Palliative (P) | 2017-07-15 | 2017-07-30 | ECX | 02 | N | CISPLATIN + RT | 100627546 |
| 10479484 | 10042545 | 1.51 | 52.8 | null | 2021-12-18 | 2021-12-22 | CABOZANTINIB | 02 | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101195190 |
| 10479687 | 10042546 | 1.8 | 70.8 | 03 | 2018-07-03 | 2018-07-03 | VINCRISTINE | 02 | N | TIVOZANIB | 101779010 |
| 10479694 | 10042547 | 1.7 | 73.3 | Curative (C) | 2018-02-15 | 2018-02-21 | EOX | 02 | N | CISPLATIN + CAPECITABINE + EPIRUBICIN | 101251254 |
| 10479741 | 10042548 | 0 | null | Palliative (P) | 2021-01-07 | 2021-01-07 | Ipilimumab | 02 | N | BLEOMYCIN | 101230082 |
| 10480076 | 10042549 | 1.55 | 83 | Adjuvant (A) | 2011-08-22 | 2019-07-30 | Letrozole + Palbociclib | 2 | N | ANAGRELIDE | 101206172 |
| 10480204 | 10042551 | 1.72 | 54 | Neo-adjuvant (N) | 2019-10-18 | 2019-11-01 | BLEOMYCIN | 2 | N | CHLORAMBUCIL + OFATUMUMAB | 101850637 |
| 10480207 | 10042552 | 1.45 | 67.7 | null | 2019-07-12 | 2019-07-19 | STAMPEDE TRIAL | null | N | CYCLOPHOSPHAMIDE | 101849012 |
| 10480292 | 10042555 | 1.75 | 63.1 | null | 2019-12-27 | 2021-10-19 | FLUOROURACIL + OXALIPLATIN | 02 | null | CISPLATIN + RT | 101710941 |
| 10480458 | 10042558 | 1.61 | 77 | Neo-adjuvant (N) | 2018-05-23 | 2018-05-23 | null | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101221005 |
| 10480551 | 10042560 | 1.64 | 84.9 | null | 2022-02-24 | 2022-02-24 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | null | OSIMERTINIB | 100806055 |
| 10480650 | 10042561 | null | null | null | 2020-04-24 | 2020-05-01 | CAPECITABINE + MITOMYCIN + RT | 02 | null | CVD | 101161113 |
| 10480710 | 10042562 | 1.92 | 72.8 | Curative (C) | 2016-10-06 | 2016-10-15 | EC + DOCETAXEL | Y | N | INTERFERON ALFA | 100014245 |
| 10480742 | 10042563 | 1.65 | null | Curative (C) | 2019-03-11 | 2019-03-16 | RCEOP | 02 | null | DABRAFENIB | 101861899 |
| 10481070 | 10042567 | 0 | null | Curative (C) | 2017-12-31 | 2017-12-31 | DHAP - R | 02 | N | RIALTO TRIAL | 101718746 |
| 10481116 | 10042570 | 1.84 | 0 | Palliative (P) | 2021-11-28 | 2021-11-28 | Fulvestrant + Palbociclib | Y | null | ISATUXIMAB + POMALIDOMIDE | 100190087 |
| 10481280 | 10042571 | 1.6 | 50.1 | 03 | 2016-07-19 | 2016-08-15 | AML 18 TRIAL | 01 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101455041 |
| 10481344 | 10042572 | 1.52 | 81.3 | Curative (C) | 2018-03-08 | 2018-03-20 | Dasatinib | 02 | N | CHLORAMBUCIL + OFATUMUMAB | 101537680 |
| 10481450 | 10042573 | 0 | null | Palliative (P) | 2021-07-30 | 2021-09-23 | REGORAFENIB | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100563695 |
| 10481585 | 10042575 | 1.51 | 91.4 | Adjuvant (A) | 2018-10-16 | 2018-10-16 | Apalutamide | 02 | null | CISPLATIN + PEMETREXED | 101268677 |
| 10481652 | 10042576 | null | null | Disease modification (D) | null | 2018-04-22 | FMD | N | N | ECX | 100743345 |
| 10481693 | 10042577 | 1.75 | 82.1 | Disease modification (D) | 2022-04-20 | 2022-04-23 | FEC + PACLITAXEL | 02 | null | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101674972 |
| 10481909 | 10042580 | 0 | 75.7 | null | 2017-08-11 | 2017-08-25 | AZACITIDINE + VENETOCLAX | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101791548 |
| 10000298 | 10042581 | 1.66 | 85.3 | null | 2019-11-27 | 2019-12-02 | Bortezomib + Panobinostat + unknown see comment | 02 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101244197 |
| 10001902 | 10042582 | 1.56 | 113.5 | null | 2020-04-30 | 2020-04-30 | Bortezomib + MELPHALAN | 99 | N | FULVESTRANT + PALBOCICLIB | 101754306 |
| 10023603 | 10042586 | 1.71 | 89.22 | Curative (C) | 2018-12-27 | 2018-12-27 | FLUOROURACIL + OXALIPLATIN | null | null | NAB-PACLITAXEL | 100822150 |
| 10025690 | 10042588 | 1.7 | 85.55 | Palliative (P) | 2020-12-10 | 2021-01-04 | Obinutuzumab + Venetoclax | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100195169 |
| 10028896 | 10042589 | 1.82 | 112.4 | null | 2017-12-17 | 2018-01-12 | ABEMACICLIB + FULVESTRANT | 02 | null | THALIDOMIDE | 101710164 |